For research use only. Not for therapeutic Use.
Sinigrin is a major glucosinolate present in plants of the Brassicaceae family. Sinigrin inhibits early-stage adipogenesis of 3T3-L1 adipocytes through the AMPK and MAPK signaling pathways. Sinigrin has potent anti-oxidant, anti-tumor and anti-inflammatory effects[1].
Sinigrin (100 μg/mL; 24 H) arrestsd cells in the G0/G1phase of the cell cycle and increased the expression of p21 and p27[1].
Sinigrin (1-100 μg/mL; 8 days) remarkably inhibits the accumulation of lipid droplets and adipogenesis by downregulating the expression of C/EBPα, PPARγ, leptin and aP2. Sinigrin increases the phosphorylation of AMPK, MAPK and acetyl-CoA carboxylase (ACC) in the early stage of adipocyte differentiation, suggesting that sinigrin has anti-adipogenic effects through AMPK, MAPK and ACC activation[1].
Sinigrin (1-100 μg/mL; 8 days) inhibits the production of pro-inflammatory cytokines including TNF-α and IL-6, IL-1β and IL-18[1].
Sinigrin (15-30 mg/kg; Oral administration; for 12 days) exerts protective and therapeutic effects on DSS‑induced colitis, by enhancing the anti-oxidant enzymes and suppressing the intestinal inflammatory cascade of markers by regulating the MAPK pathway[2].
| Catalog Number | R022274 |
| CAS Number | 3952-98-5 |
| Synonyms | potassium;[(E)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate |
| Molecular Formula | C10H16KNO9S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H17NO9S2.K/c1-2-3-6(11-20-22(16,17)18)21-10-9(15)8(14)7(13)5(4-12)19-10;/h2,5,7-10,12-15H,1,3-4H2,(H,16,17,18);/q;+1/p-1/b11-6+;/t5-,7-,8+,9-,10+;/m1./s1 |
| InChIKey | QKFAFSGJTMHRRY-OCFLFPRFSA-M |
| SMILES | C=CCC(=NOS(=O)(=O)[O-])SC1C(C(C(C(O1)CO)O)O)O.[K+] |
| Reference | [1]. Lee HW, et al. Inhibitory effect of sinigrin on adipocyte differentiation in 3T3-L1 cells: Involvement of AMPK and MAPK pathways. Biomed Pharmacother. 2018 Jun;102:670-680. [2]. Rama Satya Sri Kotipalli, et al. Sinigrin Attenuates the Dextran Sulfate Sodium-induced Colitis in Mice by Modulating the MAPK Pathway. Inflammation. 2023 Jun;46(3):787-807. |
